Plasma levels of GDF15, a member of the transforming growth factor‐β superfamily, are increased in diabetes, cardiovascular disease, chronic inflammatory diseases, and NAFLD (Adela & Banerjee, 2015; Hsiao et al., 2000; Li et al., 2018; Moon et al., 2020). This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatotic liver disease.